Icagen has entered into a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders.  The program incorporates Icagen’s platform for ion channels and is directed at a specific novel ion channel target expressed in neurons. “We are excited about partnering with Roche to develop treatments for difficult to treat neurological diseases and look forward to collaborating with them to h...